LDL
Pfizer launches cardiovascular research competition
April 10, 2015Research and Development, Sales and Marketing Amgen, Astellas, LDL, PCSK9, Pfizer, bococizumab, inhibitors
Pfizer is funding a new competitive grants programme to support research projects in the burgeoning, competitive area of cholesterol-lowering PCSK9 …
Success for Amgen’s ‘bad’ cholesterol injection
March 18, 2014Research and Development, Sales and Marketing Amgen, LDL, PCSK9, evolocumab, hofh, tesla
An investigational PCSK9 Inhibitor from Amgen has reduced LDL-C (‘bad’ cholesterol) in patients suffering from a rare genetic disorder in …
Phase III boost for alirocumab
October 17, 2013Sales and Marketing LDL, Regeneron, alirocumab
Sanofi and Regeneron Pharmaceuticals are celebrating some upbeat data from their investigational treatment alirocumab, which has proved adept at tackling …
Blow for BioInvent as vascular treatment fails
July 11, 2012Research and Development, Sales and Marketing BI-204, BioInvent, LDL, Sweden
Swedish biotech company BioInvent has suffered a new blow with the failure of its lead pipeline candidate. The company’s share …
Sanofi sets up cholesterol drug showdown with Amgen
March 27, 2012Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi
Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other. Both drugs …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
